Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Higher quality of molecular testing, an unfulfilled priority: Results from external quality assessment for KRAS mutation testing in colorectal cancer.

The Journal of molecular diagnostics : JMD - 1 May 2014

Tembuyser Lien, Ligtenberg Marjolijn J L, Normanno Nicola, Delen Sofie, van Krieken J Han, Dequeker Elisabeth M C

Abstract excerpt

Precision medicine is now a key element in clinical oncology. RAS mutational status is a crucial predictor of responsiveness to anti-epidermal growth factor receptor agents in metastatic colorectal cancer. In an effort to guarantee high-quality testing services in molecular pathology, the European Society of Pathology has been organizing an annual KRAS external quality assessment program since 2009. In 2012, 10...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Colon
Share to Colorectal Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Mutational Analysis

Share to Genotyping Techniques

Share to Proto-Oncogene Proteins

Share to Proto-Oncogene Proteins p21(ras)

Share to ras Proteins

Share to Rectum

Source

Identifiers

PMID: 24631467
DOI: 10.1016/j.jmoldx.2014.01.003

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Higher quality of molecular testing, an unfulfilled priority: Results from external quality assessment for KRAS mutation testing in colorectal cancer.PMID 24631467Read ↗

External quality assessment unravels interlaboratory differences in quality of RAS testing for anti-EGFR therapy in colorectal cancer.Semantic proximity Read ↗

External quality assessment for KRAS testing is needed: setup of a European program and report of the first joined regional quality assessment rounds.Semantic proximity Read ↗

Molecular genetics external quality assessment pilot scheme for KRAS analysis in metastatic colorectal cancer.Semantic proximity Read ↗

KRAS mutations testing in colorectal carcinoma patients in Italy: from guidelines to external quality assessment.Semantic proximity Read ↗

The Italian external quality assessment for RAS testing in colorectal carcinoma identifies methods-related inter-laboratory differences.Semantic proximity Read ↗

KRAS mutation analysis on low percentage of colon cancer cells: the importance of quality assurance.Semantic proximity Read ↗

Performance and Cost Efficiency of KRAS Mutation Testing for Metastatic Colorectal Cancer in Routine Diagnosis: The MOKAECM Study, a Nationwide ExperienceSemantic proximity Read ↗

A Multicenter Blinded Study to Evaluate KRAS Mutation Testing Methodologies in the Clinical SettingSemantic proximity Read ↗

The homogeneous mutation status of a 22 gene panel justifies the use of serial sections of colorectal cancer tissue for external quality assessment.Semantic proximity Read ↗

How close are we to standardised extended RAS gene mutation testing? The UK NEQAS evaluation.Semantic proximity Read ↗

External quality assessment of BRAF molecular analysis in melanoma.Semantic proximity Read ↗

Improvement in the quality of molecular analysis of EGFR in non-small-cell lung cancer detected by three rounds of external quality assessment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.